CopyMark Law Group
4.9/5
Drawing for ORPIPSO

USPTO serial 87900875

ORPIPSO

Reviewed by CopyMark Law Group

Reg. 5779009Status 710
Filing date
Status date
Registration date
Jun 18, 2019
Examiner
FATHY, DOMINIC
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with ORPIPSO?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Miriam D. Trudell

Miriam D. Trudell Davis Graham & Stubbs LLC3400 Walnut Street, Suite 700Denver, CO 80205United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical and veterinary preparations for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease, antibiotics; sanitary preparations for medical purposes; biotechnological preparations for medical purposes for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease, antibiotics; biological preparations for medical purposes for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease, antibiotics; drugs for medical purposes for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease, antibiotics; pharmaceuticals for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease, antibiotics; multivitamins preparations; pharmaceutical preparations for diagnosis for medical orveterinary purposes; nutraceutical preparations for therapeutic or medical purposes for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease, antibiotics; preparations of microorganisms for medical and veterinary use for the treatment of cardiovascular disease, central nervous system disease and disorders, neurological disorders, urological, urogenital and urinary disorders, gastrointestinal disorders, musculoskeletal disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious disease, auto-immune disease, antibioticsSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 2, 2026C8..CANCELLED SEC. 8 (6-YR)—
Nov 14, 2024TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Nov 14, 2024ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Nov 14, 2024ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 14, 2024REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jun 18, 2024REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Jun 18, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Apr 2, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 2, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 13, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 26, 2019FIXDELECTRONIC RECORD REVIEW COMPLETE—
Feb 22, 2019ERRRON HOLD - ELECTRONIC RECORD REVIEW REQUIRED—
Feb 20, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 19, 2019TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 19, 2019CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 13, 2019ALIEASSIGNED TO LIE—
Feb 7, 2019TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 21, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 21, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 21, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 21, 2018DOCKASSIGNED TO EXAMINER—
May 9, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 3, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance